Abstract: The invention relates to a method of reducing chronic inflammatory pain in a human subject with androgen deficiency symptoms, as defined in the instant invention, comprising transdermally administering a pain-reducing amount of a composition comprising a bioactive androgen to a human subject on a daily basis. The invention further relates to a method of increasing the pain threshold of a human subject having symptoms of androgen deficiency comprising transdermally administering a composition comprising a pain threshold-increasing amount of a bioactive androgen to a human subject with androgen deficiency symptoms on a daily basis. The invention may be used to treat both a female subject and a male subject in order to either alleviate chronic inflammatory pain or to raise the subject's pain threshold. In addition, the invention also relates to increasing the levels of endogenous opioid peptides in a human subject by administering an androgen composition to the subject.

Abstract: Methods are provided for reducing chronic inflammatory pain, increasing the levels of endogenous opioid peptides, as well as increasing the pain threshold of a subject having symptoms of androgen deficiency, comprising transdermally administering a composition comprising a bioactive androgen on a daily basis. In addition, the invention also relates to increasing the levels of endogenous opioid peptides in a human subject by administering an androgen composition to the subject. The invention also encompasses administration of a composition consisting essentially of an androgen for the treatment of chronic inflammatory pain, and for increasing the pain-threshold in a subject.

Abstract: The invention relates to a method of reducing chronic inflammatory pain in a human subject with androgen deficiency symptoms comprising transdermally administering a pain-reducing amount of a composition comprising a bioactive androgen to the subject on a daily basis. The invention relates to a method of increasing the pain threshold of a human subject having symptoms of androgen deficiency comprising transdermally administering a composition comprising a pain threshold-increasing amount of a bioactive androgen to the subject with androgen deficiency symptoms on a daily basis. The invention may be used to treat males and females in order to alleviate chronic inflammatory pain or to raise the subject's pain threshold. The invention also relates to increasing the levels of endogenous opioid peptides in a human subject by administering an androgen composition to the subject.

Abstract: The invention relates to methods for the treatment of fibromyalgia and chronic fatigue syndrome by administration of a transdermally applied androgen composition. The treatment is both safe and effective for treating fibromyalgia-related pain and fatigue, as well as chronic fatigue syndrome.

Abstract: Compositions and methods for alleviating the symptoms associated with chronic fatigue syndrome and fibromyalgia syndrome are provided. The compositions are based on use of a transdermal gel formulation delivery system for androgens, either alone or in combination with other hormones.

Abstract: The invention relates to methods for the treatment of fibromyalgia and chronic fatigue syndrome by administration of a transdermally applied androgen composition. The treatment is both safe and effective for treating fibromyalgia-related pain and fatigue, as well as chronic fatigue syndrome.

Abstract: The invention relates to methods for the treatment of fibromyalgia and chronic fatigue syndrome by administration of a transdermally applied androgen composition. The treatment is both safe and effective for treating fibromyalgia-related pain and fatigue, as well as chronic fatigue syndrome.

Abstract: Methods are provided for reducing chronic inflammatory pain, increasing the levels of endogenous opioid peptides, as well as increasing the pain threshold of a subject having symptoms of androgen deficiency, comprising transdermally administering a composition comprising a bioactive androgen on a daily basis. In addition, the invention also relates to increasing the levels of endogenous opioid peptides in a human subject by administering an androgen composition to the subject. The invention also encompasses administration of a composition consisting essentially of an androgen for the treatment of chronic inflammatory pain, and for increasing the pain-threshold in a subject.

Abstract: The invention relates to a method of reducing chronic inflammatory pain in a human subject with androgen deficiency symptoms comprising transdermally administering a pain-reducing amount of a composition comprising a bioactive androgen to the subject on a daily basis. The invention relates to a method of increasing the pain threshold of a human subject having symptoms of androgen deficiency comprising transdermally administering a composition comprising a pain threshold-increasing amount of a bioactive androgen to the subject with androgen deficiency symptoms on a daily basis. The invention may be used to treat males and females in order to alleviate chronic inflammatory pain or to raise the subject's pain threshold. The invention also relates to increasing the levels of endogenous opioid peptides in a human subject by administering an androgen composition to the subject.

Abstract: The invention relates to methods for the treatment of fibromyalgia and chronic fatigue syndrome by administration of a transdermally applied androgen composition. The treatment is both safe and effective for treating fibromyalgia-related pain and fatigue, as well as chronic fatigue syndrome.

Abstract: Compositions and methods for alleviating the symptoms associated with chronic fatigue syndrome and fibromyalgia syndrome are provided. The compositions are based on use of a transdermal gel formulation delivery system for androgens, either alone or in combination with other hormones.

Abstract: Compositions and methods for alleviating the symptoms associated with chronic fatigue syndrome and fibromyalgia syndrome are provided. The compositions are based on use of a transdermal gel formulation delivery system for androgens, either alone or in combination with other hormones.